
Benzinga Pro data, Arcus Biosciences (NYSE:RCUS) reported Q1 sales of $18.00 million. Earnings fell to a loss of $67.99 million, resulting in a 124.34% decrease from last quarter. In Q4, Arcus Biosciences earned $279.37 million, and total sales reached $354.50 million.